⟵ Back to Search Results

BGB-A317-302

Active, not recruiting

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Beigene Study ID info

BGB-A317-302

ClinicalTrials.gov ID info

NCT03430843

EudraCT Number info

2017-003699-30

China Drug Trials ID info

CTR20171026

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents